ARV-102

N/A

Report date: 2024/11/06 14:04:24
NME

Base Information

Drug NameARV-102
Drug Alias NameARV-102
ClassificationSmall molecules > Proteolysis-Targeting Chimera (PROTAC)
Mechanisms of ActionLeucine-rich repeat serine/threonine-protein kinase 2 degraders
TargetsLeucine-rich repeat serine/threonine-protein kinase 2
Therapy Area/IndicationsSupranuclear Palsy, ProgressiveParkinson Disease
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesArvinas Inc
China Registration ClassN/A

Develop Information

Active CompaniesArvinas Inc
Inactive CompaniesN/A
Active IndicationsSupranuclear Palsy, ProgressiveParkinson Disease
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A